Clinically relevant CTD assays, made with the quality you expect.
Make a difference aiding in the diagnosis of connective tissue disease and order EliATM CTD assays for laboratory testing today.
What is the EliA connective tissue disease portfolio?
A collection of clinically relevant CTD assays
Offered to support a wide variety of diagnostic needs.
Autoantibodies/antigens |
EliA assay name |
Assays within EliA SymphonyS test |
U1-RNP (A, C, 70 kDa) |
EliA U1RNP |
X |
SmD3 |
EliA SmDP-S |
X |
SS-A/Ro (52 kDa, 60 kDa) |
EliA Ro |
X |
SS-B/La |
EliA La |
X |
Centromere |
EliA CENP |
X |
Topoisomerase I/Scl-70 |
EliA Scl-70S |
X |
Histidyl-tRNA-synthetase/Jo-1 |
EliA Jo-1 |
X |
dsDNA |
EliA dsDNA |
|
RNA Polymerase III |
EliA RNA Pol III |
|
Ribosomal P-protein/Rib-P |
EliA Rib-P |
|
RNP70 |
EliA RNP70 |
|
SS-A/Ro (52 kDa) |
EliA Ro52 |
|
SS-A/Ro (60 kDa) |
EliA Ro60 |
Less false positives
High specificity due to the selection and use of recombinant antigens in this portfolio means laboratories can help reduce the number of false positives, aiding clinicians in prescribing appropriate therapies.1
Laboratory efficient
On PhadiaTM Laboratory Systems[LINK TO PHADIA PAGE], the EliA portfolio may help to reduce labor costs and hands-on time with onboard dilution, random access, and calibration curves stored for every isotype (IgG, IgA, IgM).2
High sensitivity and specificity1,3,4
Even for difficult-to-detect antibodies, such as anti-SS-A/Ro or anti-Jo-1, high quality EliA antigens can help identify important antibodies associated with CTD.5,6
View EliA assays in our product catalog
Why use EliA assays to aid in diagnosing connective tissue disease?
High quality antigens ensure highly specific and sensitive assays
Many antigens used in EliA CTD assays are manufactured using innovative human recombinant protein technology which allows for optimized accessibility and purity, increasing the clinical utility of these assays. 1,3,4
Optimized for routine testing and lean working
EliA CTD assays are fully automated solid-phase fluorescence enzyme immunoassays (FEIA) performed on Phadia Laboratory Systems, optimizing laboratory workflow efficiency and throughput while minimizing turnaround time.
How do you interpret EliA CTD portfolio assays?
EliA CTD portfolio laboratory testing interpretation
Using tests like the EliA SymphonyS and other tests within the EliA CTD portfolio may help in differentiating between a wide range of connective tissue diseases.
Prevalence of EliA CTD portfolio’s specific markers found in CTD:8-18
View all EliA assays for connective tissue disease in our product catalog
For additional information on EliA CTD assays, autoimmune diseases, and educational tools and resources, contact our experts.
Resources
Whether you’re a healthcare provider or laboratorian, Thermo Fisher Scientific offers valuable resources geared to your specific needs.
These products may not be cleared for use in your country. Please contact your sales representative for information about specific product availability.
- Orme ME, Andalucia C, Sjolander S, Bossuyt X. A comparison of a fluorescence enzyme immunoassay versus indirect immunofluorescence for initial screening of connective tissue diseases: Systematic literature review and meta-analysis of diagnostic test accuracy studies. Best Pract Res Clin Rheumatol. 2018;32(4):521-34.
- Phadia 250 User Manual. Edition 2.2. 2017: pg 9, 217
- van der Pol P, Bakker-Jonges LE, Kuijpers J, Schreurs MWJ. Analytical and clinical comparison of two fully automated immunoassay systems for the detection of autoantibodies to extractable nuclear antigens. Clin Chim Acta. 2018;476:154-9.
- Alsaed OS, Alamlih LI, Al-Radideh O, Chandra P, Alemadi S, Al-Allaf AW. Clinical utility of ANA-ELISA vs ANA-immunofluorescence in connective tissue diseases. Sci Rep. 2021;11(1):8229.
- Bossuyt, Xavier, and Ariane Luyckx. “Antibodies to extractable nuclear antigens in antinuclear antibody-negative samples.” Clinical chemistry vol. 51,12 (2005): 2426-7. doi:10.1373/clinchem.2005.058552
- Agmon-Levin, Nancy et al. “International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies.” Annals of the rheumatic diseases vol. 73,1 (2014): 17-23. doi:10.1136/annrheumdis-2013-203863
- Bizzaro N, Brusca I, Previtali G, Alessio MG, Daves M, Platzgummer S, et al. The association of solid-phase assays to immunofluorescence increases the diagnostic accuracy for ANA screening in patients with autoimmune rheumatic diseases. Autoimmun Rev. 2018;17(6):541-7.
- Yoshimi R, Ueda A, Ozato K, Ishigatsubo Y. Clinical and pathological roles of Ro/SSA autoantibody system. Clin Dev Immunol. 2012;2012:606195. doi: 10.1155/2012/606195. Epub 2012 Dec 6. PMID: 23304190; PMCID: PMC3523155.
- Conti F, Ceccarelli F, Perricone C, et al. Systemic Lupus Erythematosus with and without Anti-dsDNA Antibodies: Analysis from a Large Monocentric Cohort. Mediators Inflamm. 2015;2015:328078. doi:10.1155/2015/328078
- Peng SL and Craft JE. Autoantibodies 1996, pp 774-782.
- Gerli L and Caponi L. Autoimmunity 2005
- Rao L, Liu G, Li C, et al. Specificity of anti-SSB as a diagnostic marker for the classification of systemic lupus erythematosus. Exp Ther Med. 2013;5(6):1710‐1714. doi:10.3892/etm.2013.1051
- Tan EM. Immunologist 1999
- Nikpour M, et al. Arthritis Research & Therapy 2011
- Martins Rocha T, Fonseca R, Rosa-Gonçalves D, et al AB0645 Anti-Ssa/ro Antibodies in A Cohort of Systemic Sclerosis Patients: The Association with Interstitial Lung Disease Annals of the Rheumatic Diseases 2016;75:1125
- Ihn H, et al. Clin Exp Immunol.1996
- Cruellas MG, Viana Vdos S, Levy-Neto M, Souza FH, Shinjo SK. Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics (Sao Paulo). 2013;68(7):909-914. doi:10.6061/clinics/2013(07)04
- Robbins, Ailsa et al. “Diagnostic Utility of Separate Anti-Ro60 and Anti-Ro52/TRIM21 Antibody Detection in Autoimmune Diseases.” Frontiers in immunology vol. 10 444. 12 Mar. 2019, doi:10.3389/fimmu.2019.00444
